Preparation and evaluation of a self-emulsifying drug delivery system of etoposide-phospholipid complex

Drug Development and Industrial Pharmacy

Volumn 37, Issue 1, 2011, Pages 103-112

  Wu, Zhongbin ^a,b   Guo, Dan ^a   Deng, Li ^a   Zhang, Yue ^a   Yang, Qiuxia ^a   Chen, Jianming ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b 73131 People's Liberation Army Hospital   (China)

Author keywords

Bioavailability; Etoposide; Phospholipid complex; Self emulsifying drug delivery system

Indexed keywords

EMULSIFYING AGENT; ETOPOSIDE; ETOPOSIDE PHOSPHOLIPID COMPLEX; MONOACYLGLYCEROL; OIL; PHOSPHOLIPID DERIVATIVE; TETRAHYDROFURAN; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG SOLUBILITY; EMULSION; HYDROPHOBICITY; MALE; NONHUMAN; RAT; SUSPENSION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; EMULSIFYING AGENTS; EMULSIONS; ETOPOSIDE; FURANS; MALE; OILS; PARTICLE SIZE; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SUSPENSIONS;

EID: 78650020977     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.495752     Document Type: Article

References (54)

1. Shirazi FH, Bahrami G, Stewart DJ, Tomiak E, Delorme F, Noel D, et al. (2001). A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. J Pharm Biomed Anal, 25:353-6.
2. Burden DA, Kingma PS, Froelich-Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB, et al. (1996). Topoisomerase II. Etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem, 271:29238-44.
3. Kaul S, Srinivas NR, Igwemezie LN, Barbhaiya RH. (1996). A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients. Semin Oncol, 23:15-22.
4. Shah JC, Chen JR, Chow D. (1989). Preformulation study of etoposide: Identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm Res, 6:408-12.
5. Tao Y, Yao Y, Ding Y, Wang H. (2006). Preparation and evaluation of etoposide solid dispersions in vitro. Zhong Nan Yao Xue, 4:250-3.
6. Yuan K, Cao D, Li M, Cao W. (2004). Preparation and bioavailability in vivo of etoposide soft capsules. Zhongguo Yi Yao Gong Ye Za Zhi, 35:279-81.
7. Wu J, Chen D. (2001). Study on the physico-chemical properties of baicalin-phospholipid complex. Zhongguo Yao Xue Za Zhi, 36:173-7.
8. Li Y, Pan WS, Chen SL, Xu HX, Yang DJ, Chan ASC. (2006). Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholipid complex in rats. Drug Dev Ind Pharm, 32:413-22.
9. Li Y, Pan WS, Chen SL, Yang DJ, Chen S, Xu HX. (2006). Studies on preparation of puerarin phytosomes and their solid dispersion. Zhongguo Yao Xue Za Zhi, 41:1162-7.
10. Zhou J, Wu Z, Ping Q, Zhou H, Xu B. (2006). Preparation and physicochemical properties of Indirubin-phospholipid complex. Zhongguo Yi Yao Gong Ye Za Zhi, 37:394-7.
11. Yue PF, Yuan HL, Xie H, Xiao XH. (2008). Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo. Drug Dev Ind Pharm, 34:708-18.
12. Morazzoni P, Magistretti MJ, Giachetti C, Zanolo G. (1992). Comparative bioavailability of silipide, a new flavanolignan complex in rats. Eur J Drug Metab Pharmacokinet, 17:39-44.
13. Morazzoni P, Montalbetti A, Malandrino S, Pifferi G. (1993). Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet, 18:289-97.
14. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. (1990). Pharmacokinetic studies on IdB 1016, a sylibinphosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet, 15:333-8.
15. Morazzoni P, Magistretti MJ, Zanolo G, Poletti P. (1989). Comparative bioavailability of IdB 1016, a new flavanolignan complex in rats. Planta Medica, 55: 654
16. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, et al. (1998). Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorlywater-soluble LTB4 inhibitor. J Pharm Sci, 87:164-9.
17. Dabros T, Yeung A, Masliyah J, Czarnecki J. (1999). Emulsification through area contraction. J Colloids Interface Sci, 210:222-4.
18. Gershanik T, Benita S. (2000). Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm, 50:179-88.
19. Gershanik T, Haltne E, Lehr CM, Benita S. (2000). Chargedependent interaction of self-emulsifying oil formulations with Caco-2 cell monolayers: Binding, effects on barrier function and cytotoxicity. Int J Pharm, 211:29-36.
20. Kommuru TR, Gurley B, Khan MA, Reddy IK. (2001). Selfemulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. Int J Pharm, 212:233-46.
21. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, et al. (2004). Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm, 274:65-73.
22. Holm R, Porter CJH, Müllertz A, Kristensen HG, Charman WN. (2002). Structured triglyceride vehicles for oral delivery of halofantrine: Examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm Res, 19:1354-61.
23. O'Driscoll CM. (2002). Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci, 15:405-15.
24. Cui ShX, Nie ShF, Li L, Wang ChG, Pan WS, Sun JP. (2009). Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetin. Drug Dev Ind Pharm, 35:603-11.
25. Gursoy RN, Benita S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother, 58:173-82.
26. Wu ZB, Guo D, Chen JM. (2009). Study on preparation and physicochemical properties of etoposide-phospholipid complex. Zhongguo Yi Yao Za Zhi, 13:1250-6.
27. Pouton CW. (1997). Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev, 25:47-58.
28. Zhang P, Liu Y, Feng N, Xu H. (2008). Preparation and evaluation of self-emulsifying drug delivery system of oridonin. Int J Pharm, 355:269-76.
29. Wu W, Wang Y, Oue L. (2006). Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm, 63:288-94.
30. Kim HJ, Yoon KA, Hahn M, Park ES, Chi SC. (2000). Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone. Drug Dev Ind Pharm, 26(5):523-9.
31. Sengupta S, Tyagi P, Velpandian T, Gupta YK, Gupta SK. (2000). Etoposide encapsulated in positively charged liposomes: Pharmacokinetics in mice and formulation stability studies. Pharmacol Res, 42:459-64.
32. Giaeomelli S, Gallo D, Apollonio P, Ferlini C, Distefano M, Morazzoni P, et al. (2002). Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci, 70(12):1447-59
33. Drew RH, Dodds Ashley E, Benjamin DK Jr, Davis RD, Palmer SM, Perfect JR. (2004). Comparative safety of amphotericin B lipid complex and amphoteriein B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation, 77(2):232-7
34. Hooshmand-Rad R, Chu A, Gotz V, Morris J, Batty S, Freifeld A. (2005). Use of amphotericin B lipid complex in elderly patients. J Infect, 50:277-87.
35. Bellmann R, Egger P, Djanani A, Wiedermann CJ. (2004). Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration. Int J Antimicrob Agents, 23:80-3.
36. Li A, Zhao L, Zhai G, Lou H, Du J. (2008). An investigation on formation mechanisms and preparation of curcumin phospholipid complex. Zhongguo Zhong Yao Za Zhi, 17:2112-7.
37. Wang Q, Xie H, Cong L, Yue P, Yuan H. (2008). Preparation and physicochemical properties of ursodeoxycholic acid-phospholipid complex. Zhongguo Yi Yao Gong Ye Za Zhi, 4:269-72.
38. Lu Y, Zhang Y, Yang Z, Tang X. (2008). Formulation of an intravenous emulsion loaded with a clarithromycin-phospholipid complex, its pharmacokinetics in rats. Int J Pharm, 366:160-9.
39. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. (2007). Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm, 330:155-63.
40. Xiao Y, Song Y, Chen Z, Ping Q. (2006). The preparation of silybinphospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm, 307:77-82.
41. Trotta M, Pattarino F, Grosa G. (1998). Formation of lecithin-based microemulsions containing n-alkanol phosphocholines. Int J Pharm, 174:253-9.
42. Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. (1998). Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm, 167:155-64.
43. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. (1992). Self-emulsifying drug delivery system: Formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res, 9:87-93.
44. Tarr BD, Yalkowsky SH. (1989). Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res, 6:40-3.
45. Sachs-Barrable K, Lee SD, Wasan EK, Thorntona SJ, Wasana KM. (2008). Enhancing drug absorption using lipids: A case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev, 60(6):692-701
46. Swenson ES, Curatolo WJ. (1992). Means to enhance penetration. Adv Drug Deliv Rev, 8:39-42.
47. Venkatesh G, Majid MIA, Mansor SM, Nair NK, Croft SL, Navaratnam V. (2010). In vitro and in vivo evaluation of selfmicroemulsifying drug delivery system of buparvaquone. Drug Dev Ind Pharm, 36(6):735-745.
48. Attivi D, Ajana I, Astier A, Demore B, Gibaud S. (2010). Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Dev Ind Pharm, 36(4):421-7.
49. Aungst BJ, Saitoh H, Burchman DL, Huang S-M, Mousa SA, Hussain MA. (1996). Enhancement of the intestinal absorption of peptides and nonpeptides. J Control Release, 41:19-31.
50. Lohikangas L, Wilen M, Einarsson M, Artursson P. (1994). Effects of a new lipid-based drug delivery system on the absorption of low molecular weight heparin (Fragmin) through monolayers of human intestinal epithelial Caco-2 cells and after rectal administration to rabbits. Eur J Pharm Sci, 1:297-305.
51. Xiong J, Guo JX, Huang LSh, Meng BY, Ping QN. (2008). The use of lipid-based formulations to increase the oral bioavailability of Panax Notoginseng Saponins following a single oral gavage to rats. Drug Dev Ind Pharm, 34:65-72.
52. Beskid G, Unowsky J, Behl CR, Siebelist J, Tossounian JL, McGarry CM, et al. (1988). Enteral, oral, and rectal absorption of ceftriaxone using glyceride enhancers. Chemotherapy, 34:77-84.
53. Constanitinides PP, Scalart JP, Lancaster C, Marcello J, Marks G, Ellens H, et al. (1994). Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm Res, 11:1385-90.
54. Yeh P-Y, Berenson MM, Samowitz WS, Kova PK, Kopecek JI. (1995). Site-specific drug delivery and penetration enhancement in the gastrointestinal tract. J Control Release, 36:109-24.